{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T21:33:39Z","timestamp":1788212019464,"version":"build-2803163510"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T00:00:00Z","timestamp":1608163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>\n                    <jats:bold>Objective:<\/jats:bold>\n                    To summarize and analyze the manifestations of stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy (SAVI).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    A systematic literature review was performed including cases from January 1, 2014, to February 1, 2020, using PubMed, OVID, CNKI, and WanFang. This included all the literature containing comparatively complete clinical data. Statistical analysis was performed using SPSS 20.0 to analyze the difference in age of onset, severity of skin lesions, and respiratory symptoms between SAVI patients with p.N154S and p.V155M mutations.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    A total of 25 papers were included reporting on 51 individuals, of whom 17 had familiar inheritance of their mutation. Patients included 27 males and 24 females, and 8 fatal cases were observed. A total of 10 mutation sites have been reported in the STING gene, with p.V155M being the most prevalent. We identified SAVI as an early-onset disease with a median age of onset of 3 months after birth. Skin lesions were the most common symptoms of SAVI, found in 94.1% (48\/51) of patients, while 76% (19\/25) who had undergone a skin biopsy showed vasculopathy. Involvement of the lungs was identified in 68.6% (35\/51) of patients, while only 22.2% (4\/18) who had undergone a lung biopsy showed vasculopathy. Of 20 patients, 19 had increased immunoglobulin, mainly IgG. Furthermore, 45.1% (23\/51) of patients had a positive low titer or were transiently positive for antinuclear antibodies. Of the 18 patients treated with JAK inhibitors, 6 relapsed and 2 died of acute respiratory failure caused by viral infection. Patients with p.N154S mutation had an earlier disease onset (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.002) and more severe skin lesions (\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.001) than those patients with p.V155M mutation.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    SAVI is an early-onset disease accompanied by skin and lung lesions whose clinical presentation varies among patients with different genotypes. Therapeutic effects of JAK inhibitors are unsatisfactory.\n                  <\/jats:p>","DOI":"10.3389\/fped.2020.577918","type":"journal-article","created":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T05:37:45Z","timestamp":1608701865000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["Stimulator of Interferon Genes-Associated Vasculopathy With Onset in Infancy: A Systematic Review of Case Reports"],"prefix":"10.3389","volume":"8","author":[{"given":"YunFan","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiuYun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZhiPeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JianXin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"QingQin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,12,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1312625","article-title":"Activated STING in a vascular and pulmonary syndrome","volume":"371","author":"Liu","year":"2014","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"5516","DOI":"10.1172\/JCI79100","article-title":"Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations","volume":"124","author":"Jeremiah","year":"2014","journal-title":"J Clin Invest."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1136\/annrheumdis-2015-eular.6115","article-title":"AB1014 enlarging the clinical spectrum of sting-associated vasculopathy with onset in infancy (SAVI)","volume":"74","author":"Caorsi","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jamadermatol.2015.0251","article-title":"Stimulator of interferon genes-associated vasculopathy with onset in infancy: a mimic of childhood granulomatosis with polyangiitis","volume":"151","author":"Munoz","year":"2015","journal-title":"JAMA Dermatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jaad.2015.10.007","article-title":"Failure to thrive, interstitial lung disease, and progressive digital necrosis with onset in infancy","volume":"74","author":"Chia","year":"2016","journal-title":"J Am Acad Dermatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1164\/rccm.201510-2102LE","article-title":"Interstitial lung disease caused by STING-associated vasculopathy with onset in infancy","volume":"194","author":"Clarke","year":"2016","journal-title":"Am J Respir Crit Care Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/j.jaci.2016.07.015","article-title":"Efficacy of the Janus kinase 1\/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children","volume":"138","author":"Fremond","year":"2016","journal-title":"J Allergy Clin Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1016\/j.chest.2016.02.682","article-title":"Severe pulmonary fibrosis as the first manifestation of interferonopathy (TMEM173 Mutation)","volume":"150","author":"Picard","year":"2016","journal-title":"Chest."},{"key":"B9","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1136\/annrheumdis-2016-209841","article-title":"Familial chilblain lupus due to a gain-of-function mutation in STING","volume":"76","author":"K\u00f6nig","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1093\/rheumatology\/kex316","article-title":"Type I interferonopathy in a young adult","volume":"56","author":"Manoussakis","year":"2017","journal-title":"Rheumatology."},{"key":"B11","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jaci.2016.10.031","article-title":"Disease-associated mutations identify a novel region in human STING necessary for the control of type I interferon signaling","volume":"140","author":"Melki","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1136\/annrheumdis-2017-eular.4489","article-title":"Sting-associated vasculopathy with onset in infancy (SAVI): a differential diagnosis of inflammatory interstitial lung disease","volume":"76","author":"Dagher","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/j.jaci.2016.10.030","article-title":"Tofacitinib relieves symptoms of stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy caused by 2 de novo variants in TMEM173","volume":"139","author":"Seo","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"key273","DOI":"10.1093\/rheumatology\/key273.006","article-title":"STING: associated vasculopathy with onset in infancy (SAVI)","volume":"57","author":"Gallagher","year":"2018","journal-title":"Rheumatology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.3389\/fimmu.2018.01535","article-title":"A Mutation outside the dimerization domain causing atypical STING-associated vasculopathy with onset in infancy","volume":"9","author":"Saldanha","year":"2018","journal-title":"Front Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3760\/cma.j.issn.0578-1310.2018.03.005","article-title":"Stimulator of interferon genes-associated vasculopathy with onset in infancy: first case report in China","volume":"56","author":"Yu","year":"2018","journal-title":"Zhonghua Er Ke Za Zhi."},{"key":"B17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1089\/ped.2019.1054","article-title":"The challenge of diagnosing SAVI: case studies","volume":"32","author":"Cao","year":"2019","journal-title":"Pediatr Allergy Immunol Pulmonol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.3389\/fimmu.2019.02770","article-title":"Novel TMEM173 mutation and the role of disease modifying alleles","volume":"10","author":"Keskitalo","year":"2019","journal-title":"Front Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1080\/03009742.2018.1550212","article-title":"First Egyptian patient with STING-associated vasculopathy with onset in infancy","volume":"48","author":"Shoman","year":"2019","journal-title":"Scand J Rheumatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s10875-019-00645-0","article-title":"Efficacy and adverse events during janus kinase inhibitor treatment of SAVI syndrome","volume":"39","author":"Volpi","year":"2019","journal-title":"J Clin Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3969\/j.issn.1673-5501.2019.03.007","article-title":"Stimulator of interferon genes-associated vasculopathy with onset in infancy: one case report and literature review","volume":"14","author":"Zhang","year":"2019","journal-title":"Chin J Evid Based Pediatr."},{"key":"B22","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1053\/j.ajkd.2019.07.010","article-title":"APOL1-Associated collapsing focal segmental glomerulosclerosis in a patient with stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy (SAVI)","volume":"75","author":"Abid","year":"2020","journal-title":"Am J Kidney Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"108273","DOI":"10.1016\/j.clim.2019.108273","article-title":"Baricitinib experience on STING-associated vasculopathy with onset in infancy: a representative case from Turkey","volume":"212","author":"Balci","year":"2020","journal-title":"Clin Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/rheumatology\/kez444","article-title":"A patient with stimulator of interferon genes-associated vasculopathy with onset in infancy without skin vasculopathy","volume":"59","author":"Carmela Gerarda Luana","year":"2020","journal-title":"Rheumatology."},{"key":"B25","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s10875-019-00690-9","article-title":"STING-Associated vasculopathy with onset in infancy in three children with new clinical aspect and unsatisfactory therapeutic responses to tofacitinib","volume":"40","author":"Tang","year":"2020","journal-title":"J Clin Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/nri3921","article-title":"STING: infection, inflammation and cancer","volume":"15","author":"Barber","year":"2015","journal-title":"Nat Rev Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1126\/science.1229963","article-title":"Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA","volume":"339","author":"Jiaxi","year":"2013","journal-title":"Science."},{"key":"B28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1600-065X.2008.00737.x","article-title":"Innate immunity to virus infection","volume":"227","author":"Osamu","year":"2009","journal-title":"Immunol Rev."},{"key":"B29","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1600-065X.2008.00731.x","article-title":"Pattern recognition receptors and control of adaptive immunity","volume":"227","author":"Palm Noah","year":"2009","journal-title":"Immunol Rev."},{"key":"B30","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nature07317","article-title":"STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling","volume":"455","author":"Hiroki","year":"2008","journal-title":"Nature."},{"key":"B31","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.it.2015.02.003","article-title":"The STING pathway and the T cell-inflamed tumor microenvironment","volume":"36","author":"Seng-Ryong","year":"2015","journal-title":"Trends Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/nature08476","article-title":"STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity","volume":"461","author":"Hiroki","year":"2009","journal-title":"Nature."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1182\/blood-2008-07-019307","article-title":"TLRs and innate immunity","volume":"113","author":"Bruce","year":"2009","journal-title":"Blood."},{"key":"B34","doi-asserted-by":"publisher","first-page":"7941","DOI":"10.1073\/pnas.1818281116","article-title":"Hierarchy of clinical manifestations in SAVI N153S and V154M mouse models","volume":"116","author":"Motwani","year":"2019","journal-title":"Proc Natl Acad Sci USA."},{"key":"B35","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jaci.2018.04.034","article-title":"Severe combined immunodeficiency in stimulator of interferon genes (STING) V154M\/wild-type mice","volume":"143","author":"Delphine","year":"2019","journal-title":"J Allergy Clin Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jaci.2019.01.044","article-title":"STING-associated lung disease in mice relies on T cells but not type I interferon","volume":"144","author":"Hella","year":"2019","journal-title":"J Allergy Clin Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1084\/jem.20171351","article-title":"STING-associated vasculopathy develops independently of IRF3 in mice","volume":"214","author":"James","year":"2017","journal-title":"J Exp Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e01806","DOI":"10.1128\/JVI.01806-18","article-title":"A human gain-of-function STING mutation causes immunodeficiency and gammaherpesvirus-induced pulmonary fibrosis in mice","volume":"93","author":"Bennion Brock","year":"2019","journal-title":"J Virol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"E7768","DOI":"10.1073\/pnas.1806239115","article-title":"Nitro-fatty acids are formed in response to virus infection and are potent inhibitors of STING palmitoylation and signaling","volume":"115","author":"Louise","year":"2018","journal-title":"Proc Natl Acad Sci USA."},{"key":"B40","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41586-018-0287-8","article-title":"Targeting STING with covalent small-molecule inhibitors","volume":"559","author":"Haag Simone","year":"2018","journal-title":"Nature."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2020.577918\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T05:37:54Z","timestamp":1608701874000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2020.577918\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,17]]},"references-count":40,"alternative-id":["10.3389\/fped.2020.577918"],"URL":"https:\/\/doi.org\/10.3389\/fped.2020.577918","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,17]]},"article-number":"577918"}}